Zafrens Expands Series A Funding to $31M for Drug Discovery Platform
- Editor
- Feb 4
- 1 min read
What's Happening: Biotech company Zafrens has added imec.xpand to its Series A funding syndicate, bringing the total capital raised to $31 million. The company's platform allows scientists to create and test hundreds of thousands of potential medicines in a single experiment, significantly reducing the time and cost of drug discovery.
The Key Moves:
Zafrens welcomes imec.xpand to its Series A syndicate, joining existing investors Prime Movers Lab, Kofa Healthcare, and Global Brain.
The company's platform enables creation and testing of hundreds of thousands of potential drugs simultaneously, providing deeper insights into drug efficacy and safety.
Funding will be used to expand Zafrens' capacity and engage in additional partnerships with pharmaceutical companies worldwide.
By The Numbers :
Total Series A funding raised: $31 million
Platform capability: Test hundreds of thousands of potential medicines in a single experiment
Existing collaborations: Several leading pharmaceutical companies
Key Quotes:
"Our platform represents a fundamental shift in drug discovery," said Swamy Vijayan, CEO of Zafrens.
"Zafrens exemplifies the kind of breakthrough innovation imec.xpand seeks to support," said Benoit Devogelaere, Partner at imec.xpand.
"Their platform is fundamentally enabled through nanotechnology, and can accelerate the development of various types of modern medicines," added Devogelaere.
The Bottom Line: Zafrens' innovative drug discovery platform has attracted significant investment, positioning the company to potentially revolutionize the pharmaceutical industry by accelerating the development of new treatments across multiple disease areas. The expanded funding and new partnerships could lead to faster, more efficient drug discovery processes and potentially bring life-changing drugs to patients more quickly.
Comentarios